Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 603 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antidepressant medication Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
View directory record Official record
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825
View directory record Official record
Conditions
Antidepressant Activity in Healthy Volunteers
Interventions
Escitalopram, Citalopram, Placebo
Drug
Lead sponsor
Michael Henry, MD
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

NCT03321006
View directory record Official record
Conditions
Hearing Loss, Depression
Interventions
Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 7, 2026, 6:23 AM EDT
Recruiting Phase 2 Interventional

Duloxetine in Inflammatory Bowel Diseases

NCT07431606
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
24 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

NCT02289248
View directory record Official record
Conditions
Depression
Interventions
Ketamine, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Not applicable Interventional

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

NCT00186264
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
venlafaxine XR, hydrocortisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 7, 2026, 6:23 AM EDT
Completed No phase listed Observational

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Withdrawn Not applicable Interventional

Electronic-Measurement Based Care for Major Depressive Disorder

NCT01583998
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
e-MBC
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 7, 2026, 6:23 AM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 2Phase 3 Interventional

Blended Collaborative Care for Heart Failure and Co-Morbid Depression

NCT02044211
View directory record Official record
Conditions
Heart Failure, Systolic, Depression, Cardiovascular Disease
Interventions
Collaborative Care for Heart Failure, Collaborative Care for Depression
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

NCT01360632
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807
View directory record Official record
Conditions
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions
Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

NCT01432236
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Tucson, Arizona • Orange, California • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 7, 2026, 6:23 AM EDT
Completed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study

NCT04933630
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

NCT00095745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
58
States / cities
Mesa, Arizona • Peoria, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Depression Care Management by E-mail

NCT00755235
View directory record Official record
Conditions
Depression
Interventions
Depression care management by secure messaging
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

NCT02473289
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Sirukumab 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Not applicable Interventional

Study to Compare the Use of a Behavioral Health App Versus Care As Usual for 16-22 Year Olds with Depression

NCT05159713
View directory record Official record
Conditions
Depression
Interventions
dCBI, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 22 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

NCT02932943
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 4 Interventional

Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)

NCT00318773
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
sertraline
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2009 · Synced Oct 7, 2026, 6:23 AM EDT
Withdrawn Phase 4 Interventional

Can Additional Drug Therapy Accelerate Response Time to Antidepressants

NCT00221494
View directory record Official record
Conditions
Depression
Interventions
citalopram + tiodothyronine, or + pindolol, or + placebo
Drug
Lead sponsor
Mark Frye
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Improving Depression Outcome by Enhancing Memory for Cognitive Therapy

NCT01790919
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Cognitive therapy for depression
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 7, 2026, 6:23 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BMS-986511, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 7, 2026, 6:23 AM EDT